Medtronic PLC

Medtronic is set to report its first-quarter fiscal 2027 results on September 1 before the market opens, with analysts expecting earnings per share of $1.39, up 10.3% year over year, and revenues of $9.47 billion, a 10.4% increase. The company has beaten estimates in each of the past four quarters, averaging a 2.3% surprise, though the current Earnings ESP is 0.00% and the stock holds a Zacks Rank #3. Growth is anticipated across all segments, with Cardiovascular revenues expected to rise 15.2%, Neuroscience 10.7%, Medical Surgical 7.6%, and Diabetes 15.1%, driven by products like the pulsed field ablation portfolio, the AiBLE ecosystem, and the MiniMed 780G system. Medtronic also completed the IPO of its MiniMed diabetes business in March, retaining about 90% ownership, and has made strategic acquisitions and investments to bolster its pipeline. The stock trades at a forward P/E of 14.98, below its historical median and the industry average, and has outperformed peers like Boston Scientific and Edwards Lifesciences over the past three months.

The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.

Danaher and Medtronic are both showing signs of recovery, but their paths differ sharply. Medtronic reported its highest annual revenue growth in 10 years in fiscal Q4 and full-year 2026, with Q4 revenue reaching $9.8 billion, up 9.9% as reported and 6.6% organic, and full-year revenue of $36.4 billion, up 8.4% as reported and 5.8% organic. Danaher, meanwhile, cut the upper end of its full-year core revenue growth outlook to 4% from 6%, while maintaining the lower end at 3%, citing weaker respiratory testing revenue. Hedge fund ownership declined for both stocks between Q4 2025 and Q1 2026, with Danaher falling from 125 funds to 110 and Medtronic from 63 to 60.

Medtronic plc's board of directors approved a cash dividend of $0.72 per ordinary share for the second quarter of fiscal year 2027. The dividend is payable on October 16, 2026, to shareholders of record at the close of business on September 25, 2026. This quarterly declaration is consistent with the dividend increase announced in June 2026. Medtronic has increased its annual dividend payment for 49 consecutive years and is a constituent of the S&P 500 Dividend Aristocrats index.

Medtronic has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter for treating atrial fibrillation and atrial flutter. The licence allows commercial use of Medtronic's combined pulse field and radiofrequency ablation technologies across Canada. The Affera system provides physicians with an all-in-one mapping and ablation platform aimed at supporting procedural efficiency and patient care. The approval marks a milestone for Medtronic's Cardiac Ablation Solutions division in the global atrial fibrillation treatment market.

A federal jury ordered Medtronic to pay US$88,000,000 in compensatory damages over injuries linked to Covidien hernia mesh, while Medtronic Canada received Health Canada approval for its Affera Integrated Mapping and Ablation System for treating atrial fibrillation and atrial flutter. The record-setting mesh verdict sharpens attention on legal and manufacturing risks, but the near-term investment focus still centers on execution in Cardiac Ablation Solutions and other growth platforms. The new Health Canada licence deepens Medtronic's footprint in atrial fibrillation treatment by adding a second pulsed field ablation option alongside PulseSelect, which could influence catheter utilization and procedure volumes if adoption continues. Medtronic's narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029, requiring 4.5% yearly revenue growth and about a $1.8 billion earnings increase from $4.8 billion today. Some of the lowest ranked analysts were already assuming slower growth, with revenue around US$38.6 billion and earnings of about US$6.2 billion by 2029, and this latest mesh verdict could reinforce that more cautious view if concerns about legal and execution risks in CAS and other platforms start to broaden.

Abbott Laboratories beat fiscal second-quarter estimates and raised its full-year adjusted diluted EPS guidance to a range of $5.45 to $5.60, up from $5.38 to $5.58, driven by a 42% surge in diagnostics sales to $3.09 billion. Medtronic reported its highest annual revenue growth in ten years, with fiscal 2026 revenue reaching $36.4 billion, up 8.4% as reported, as newer platforms like Symplicity Spyral, now annualizing at approximately $100 million, gained traction. Abbott reaffirmed its full-year comparable sales growth outlook of 6.5% to 7.5%, while Medtronic faces an estimated $250 million tariff headwind in fiscal 2027. Hedge fund ownership of Abbott rose to 73 funds in the first quarter of 2026, while Medtronic's declined to 60.

Orchestra BioMed announced that its BACKBEAT global pivotal trial, conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by the end of the third quarter of 2026, with primary data presentation targeted for the second quarter of 2027. The company reported a cash balance of $110 million as of June 30, 2026, providing projected runway into the fourth quarter of 2027, following $35 million in strategic capital from Medtronic and Ligand during the quarter. AVIM Therapy received a second FDA Breakthrough Device Designation, now covering both the broad group of patients with uncontrolled hypertension and elevated cardiovascular risk and the pacemaker-indicated group studied in the BACKBEAT Trial. The Virtue pivotal trial for coronary in-stent restenosis is advancing with further site activations and patient enrollments. Orchestra BioMed will host an R&D Day on November 12, 2026, in New York City to review both programs.

UBS upgraded Medtronic to Buy from Neutral, telling investors a turnaround is underway at the medical-device company. The upgrade follows Medtronic's report of its highest annual revenue growth in 10 years, with fiscal Q4 revenue reaching $9.8 billion, up 9.9% as reported and 6.6% organic, and full-year fiscal 2026 revenue of $36.4 billion, up 8.4% as reported and 5.8% organic. Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth, and the Symplicity Spyral hypertension platform is now annualizing at $100 million. Management noted tariffs created a $74 million headwind in the quarter and expects a roughly $250 million impact in fiscal 2027, while guiding for organic revenue growth of 6.75% to 7.25% for the year.

Medtronic has received an expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter, allowing treatment of ventricular arrhythmias. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, underscoring its potential clinical impact. This broader regulatory clearance could strengthen Medtronic's position in cardiac arrhythmia care across international markets, though it represents a step in a longer commercialization path rather than an immediate shift in the overall business mix.

Medtronic’s stock could rise more than 40% from its current price of $86 to hit a high-end Wall Street target of $121 by the end of 2026, according to a Motley Fool analysis. The medical device maker’s shares have slumped over 30% in the past five years amid higher costs, supply chain issues, and competitive pressure, but its restructuring efforts are gaining traction. In fiscal 2026, revenue grew 8.4% to $36.4 billion, marking its strongest top-line growth in a decade, while analysts project earnings per share to grow at a compound annual rate of 13% through fiscal 2029. The company recently spun off its diabetes unit as MiniMed and is expanding higher-margin cardiovascular and neuroscience portfolios while integrating AI into surgical planning. Even at $121, the stock would trade at just 18 times next year’s earnings and offers a 3.3% forward dividend yield, with a potential Dividend King milestone next year if it raises its payout for the 50th consecutive year.

A new mini-documentary series by Nicely Done Productions reveals the hidden infrastructure of modern life, hosted on National Geographic's global digital platform. The series, Threads of Connectivity, follows five companies building the systems that keep modern life moving, with each episode focusing on a global company solving a critical problem. Boldyn Networks is delivering 5G across Rome's metro serving 18 million people in what it calls the largest smart city connectivity project ever built in Italy, while Medtronic is advancing spine surgery through its AiBLE smart ecosystem. Genesys is redesigning customer service around agentic AI as Europe writes new rules for responsible AI, Carrier is turning homes into intelligent energy systems to reduce grid strain, and OATI builds software to keep the grid stable as renewables and electric vehicles flood networks worldwide. The series is available on NatGeo.com.

Medtronic is one annual increase away from becoming a Dividend King after raising its payout for the 49th consecutive year in June. The medical device maker’s stock has fallen 33% over five years and trades at $87, or 15 times forward earnings, with a 3.4% forward yield. Wall Street analysts hold a median price target of $100 per share and none rate the stock a sell. In fiscal 2026, revenue rose 8.4% to $36.4 billion, the strongest top-line growth in a decade, and free cash flow reached $5.43 billion, comfortably covering $3.64 billion in dividends. Analysts project revenue and earnings per share to grow at compound annual rates of 5% and 13%, respectively, through fiscal 2029, supported by new products such as the Affera Pulsed Field Ablation system, the Symplicity Spyral renal denervation system, and the Hugo robotic-assisted surgery platform.

Medtronic has completed its $650 million acquisition of SPR Therapeutics and formally launched the ViaVerte system at ASPN 2026, expanding its pain therapy portfolio. The deal adds a non-opioid pain management platform to Medtronic's existing medical device offerings, strengthening its position in interventional pain therapies as clinicians seek alternatives to opioids. The move gives Medtronic a larger footprint in chronic pain treatment and adds a distinct product line alongside its robotics and AI platforms. Medtronic trades at $84.22, roughly 14% below the analyst target of $97.84, and the stock is up 4.0% over the past 30 days.

The American robotics industry has entered a decisive acceleration phase in 2026, with June and July emerging as a landmark period across physical AI, surgical systems, defense autonomy, and elder care. In June, BMW Group announced plans to deploy Figure AI's third-generation Figure 03 humanoid at its Spartanburg plant, while NEURA Robotics closed a Series C worth up to $1.4 billion, and humanoid startups have raised $8.6 billion in 2026, 1.8 times the full-year 2025 total. On July 22, the FDA granted de novo authorization to Johnson & Johnson's Ottava system for ten general surgery procedures, breaking a long era of single-platform dominance, and Medtronic unveiled its AI-native Touch Surgery Aide platform. Defense robotics drew fresh capital with Mach Industries raising $300 million and Shifters securing $10.2 million, while the global elder care assistive robot market is projected at $3.9 billion in 2026, reaching $9.8 billion by 2033. Synopsys raised its fiscal 2026 revenue guidance to $9.665 billion at midpoint, AMD unveiled its Ryzen AI Embedded X100 Series for robotics, Manhattan Associates reaffirmed full-year guidance of $1.15 billion in revenues, and UiPath targets fiscal 2027 ARR of approximately $2.06 billion.

The global robotic endoscopy devices market is projected to grow from $2.8 billion in 2025 to $6.5 billion by 2034, at a compound annual growth rate of approximately 10%, according to a report by DelveInsight. North America accounted for about 42% of global revenue in 2025, driven by widespread adoption of robotic-assisted surgical technologies and the presence of major players such as Intuitive Surgical, Medtronic, and Johnson & Johnson MedTech. The therapeutic robotic endoscopes category was the largest product segment, while the Asia-Pacific region is expected to see the highest growth due to aging populations and rising investments in robotic surgery. Key companies in the market include Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Olympus, Boston Scientific, FUJIFILM, Stryker, KARL STORZ, Asensus Surgical, and CMR Surgical. Recent developments include FDA clearance of Medtronic's Hugo system for urologic procedures in December 2025 and FDA 510(k) clearance of CMR Surgical's Versius Plus system for cholecystectomy.

The global electrophysiology market is projected to grow from USD 12.89 billion in 2025 to USD 43.05 billion by 2035, at a compound annual growth rate of 12.79%, according to a new report by SNS Insider. Ablation catheters held the largest product segment share at 46.82% in 2025, while pulse field ablation is the fastest-growing segment with a CAGR of 17.64%. North America led the market with a 42.37% revenue share in 2025, and the Asia Pacific region is expected to grow the fastest at a 14.44% CAGR through 2035. Key companies include Abbott Laboratories, Medtronic, Johnson & Johnson MedTech, Boston Scientific, and Philips Healthcare.

The global digital biomarkers market is projected to grow from USD 5.84 billion in 2025 to USD 35.83 billion by 2035, at a compound annual growth rate of 19.89 percent, according to a new report by SNS Insider. North America held the largest revenue share in 2025 at 39.27 percent, while the Asia-Pacific region is expected to be the fastest-growing market with a CAGR of 21.07 percent from 2026 to 2035. Cloud-based deployment led with a 46.11 percent share in 2025, and physiological biomarkers dominated the biomarker type segment at 38.45 percent. The neurology application segment accounted for 32.28 percent of the market, and pharmaceutical and biopharma companies were the leading end users with a 36.94 percent share. Key players include Apple, Alphabet, Microsoft, Samsung, and Medtronic.

Medtronic is unveiling Touch Surgery Aide, an AI-native surgical computing platform that enables real-time artificial intelligence during procedures, at the Society of Robotic Surgery 2026 Annual Meeting in Florida. Built on NVIDIA accelerated computing infrastructure including Holoscan, CUDA, and TensorRT, the platform powers the Touch Surgery ecosystem, which is already used in more than 1,500 operating rooms worldwide. Medtronic also announced FDA clearance of Instrument Exit Point, the first real-time AI application for robotic procedures from Medtronic, which runs on Touch Surgery Aide and provides visual notifications when select instruments move beyond the visible field of view during robotic surgery using the Hugo robotic-assisted surgery system. The Hugo system received FDA clearance for urologic procedures in December 2025 and has been used in tens of thousands of procedures across more than 35 countries. Medtronic expects the platform to eventually support a growing range of real-time AI applications and connect with other Medtronic technologies in the operating room.

Medtronic has completed its acquisition of SPR Therapeutics, adding a minimally invasive, non-opioid peripheral nerve stimulation system to its pain therapy portfolio. The deal brings the SPRINT system under Medtronic's umbrella, giving the company a short-term therapy option that can sit alongside its existing spinal cord and implanted neuromodulation devices for chronic and acute pain. This move expands Medtronic's presence in earlier-stage pain interventions and aligns with a broader healthcare push to reduce reliance on opioid medications. Integration of the smaller, focused platform will require careful commercial execution, pricing decisions, and reimbursement alignment to ensure clinically appropriate use. The acquisition also positions Medtronic as a more comprehensive partner for pain clinics versus large device peers such as Abbott and Boston Scientific.

Medtronic and Apollo Hospitals have inaugurated an 11-bed state-of-the-art intensive care unit at Apollo Hospitals, Jubilee Hills in Hyderabad. The facility is fully integrated with Medtronic's advanced Acute Care and Monitoring technologies and will serve as a real-world clinical innovation hub for Medtronic's research and development. The partnership was formalized through a memorandum of understanding signed by Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, Manpreet Singh, CEO of Apollo HealthAxis, and Mandeep Singh Kumar, Managing Director and Vice President for India Subcontinent Countries at Medtronic. Leaders from both organizations emphasized that the collaboration aims to enhance critical care infrastructure, enable more informed care delivery, and support the development of technologies designed to improve patient outcomes in India and globally.

Medtronic voluntarily initiated a Class II recall of 590 Octopus 4 Tissue Stabilizer devices in May 2026 after discovering an assembly issue in the tubing configuration, with the US FDA listing the action as an ongoing enforcement event affecting worldwide distribution. Around the same time, the company reported fiscal Q3 2024 earnings per share of US$1.30 on revenue of US$8.09 billion, exceeding expectations. The recall appears limited in scope and does not obviously alter the near-term focus on margin recovery, though it highlights the balance between quality-control challenges and financial execution. Medtronic's narrative projects US$41.5 billion in revenue and US$6.6 billion in earnings by 2029, requiring 4.5% yearly revenue growth and about a US$1.8 billion earnings increase from US$4.8 billion today. Some analysts already assumed only about 2% annual revenue growth to roughly US$38.6 billion and EPS near US$4.89 by 2029, and this latest recall could push their more cautious view on execution and quality control even further.

The global surgical robots market is projected to grow from USD 13.69 billion in 2025 to USD 27.14 billion by 2030, at a compound annual growth rate of 14.7%, according to a new report by MarketsandMarkets. Growth is driven by increasing demand for minimally invasive surgeries, rising surgical volumes linked to chronic diseases and an aging population, and advances in robotic platforms, 3D visualization, AI-assisted navigation, and surgical instrumentation. Instruments and accessories represent the largest offering segment, general surgery is the largest application segment, and hospitals and clinics are the largest end-user segment. Asia Pacific is expected to be the fastest-growing regional market, with key players including Intuitive Surgical, Stryker Corporation, Medtronic, Smith+Nephew, and Zimmer Biomet.

The global blood glucose monitoring system market is projected to grow from USD 16.8 billion in 2025 to USD 39.4 billion by 2035, at a compound annual growth rate of 8.9%. The market is expected to reach USD 18.3 billion in 2026. Growth is driven by the introduction of AI-enabled monitoring systems, such as Roche's Accu-Chek SmartGuide continuous glucose monitoring solution launched in the Middle East in November 2025, and the rising prevalence of home healthcare. North America held the highest market share in 2025, while Asia Pacific is expected to capture a significant revenue share due to an aging population and increasing product launches. Key players include Abbott Laboratories, Medtronic, and Dexcom.

Medtronic shares reached a session high on Friday amid hopes of expanded reimbursement for renal denervation, a hypertension therapy used in the company’s Symplicity Spyral Renal Denervation System. The uptick came after the AMA CPT Editorial Panel released a Proposed Panel Agenda for its upcoming meeting, including a proposal to establish permanent Category I codes for RDN therapy. Leerink Partners analyst Mike Kratky called this a meaningful potential step towards expanded reimbursement that could incrementally drive adoption for Medtronic's RDN business. Subject to a positive review at the September 2026 meeting, the proposed migration from Category III to Category I indicates that available clinical data and utilization trends are supportive of granting a permanent code for RDN. While a favorable Panel action would not by itself guarantee coverage or a payment rate, it de-risks the reimbursement pathway that has been a key overhang on RDN adoption since the technology's launch.

Medtronic shares have risen about 1.5% since its last earnings report, outperforming the S&P 500. The company posted fourth-quarter fiscal 2026 adjusted earnings of $1.55 per share, down 4.3% year over year but above the Zacks Consensus Estimate by 0.6%, while revenue rose 9.9% to $9.81 billion, beating estimates by 1.5%. Full-year revenue reached $36.4 billion, up 8.4%, with adjusted earnings of $5.53 per share. Medtronic guided for fiscal 2027 organic revenue growth of 6.75% to 7.25% and adjusted earnings of $5.90 to $6.00 per share, and increased its quarterly dividend to $0.72 per share, marking its 49th consecutive year of dividend increases.

Medtronic and Retia Medical have expanded their commercial relationship to include the distribution of the Argos Cardiac Output Monitor. The partnership aims to bring Retia's hemodynamic monitoring technology to clinicians managing high-risk surgical and critically ill patients, with a focus on expanding into new markets including Europe. The integration of Medtronic's Acute Care & Monitoring Technologies, such as INVOS, with accurate hemodynamic monitoring is expected to help personalize patient care. The Argos Cardiac Output Monitor will also expand Medtronic's portfolio while providing meaningful cardiovascular insights.